57 recruiting, 44 active not recruiting, 10 completed, 9 not yet recruiting. 131 Phase 3, 28 Phase 2.
Follow MRI: new trials by email Literature Review of MRI trials Research Report on MRI
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 400 | 2027-02-10 | 2026-07-08 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 920 | 2026-12-23 | 2026-10-22 |
| Testing Short-Course Radiation Versus Standard-Course Radiation for Soft Tissue Sarcomas That Need Surgery and Radiation 3-Dimensional Conformal Radiation Therapy, Biospecimen Collection, Computed Tomography - Recurrent Soft Tissue Sarcoma of the Trunk and Extremities, Resectable Soft Tissue Sarcoma of the Trunk and Extremities | Phase 3 | Recruiting | SWOG Cancer Research Network | 296 | 2026-12-02 | 2026-10-13 |
| PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma Chemical Exchange Saturation Transfer Magnetic Resonance Imaging, Contrast-enhanced Magnetic Resonance Imaging, Magnetic Resonance Imaging - Glioblastoma | Phase 3 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 60 | 2026-12-01 | 2026-07-07 |
| Pembrolizumab and Radiation Therapy With or Without Neoadjuvant Doxorubicin and Ifosfamide for the Treatment of High-Risk Resectable Undifferentiated Pleomorphic Sarcoma or Liposarcoma of the Extremity or Trunk Wall Biospecimen Collection, Computed Tomography, Doxorubicin - Resectable Liposarcoma, Resectable Soft Tissue Sarcoma | Phase 3 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 228 | 2026-12-01 | 2026-09-16 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial Bevacizumab, Biopsy Procedure, Biospecimen Collection - Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma | Phase 3 | Recruiting | City of Hope Medical Center | 129 | 2026-10-01 | 2026-09-25 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin Biospecimen Collection, Carboplatin, Cetuximab - Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma | Phase 3 | Recruiting | NRG Oncology | 454 | 2026-07-31 | 2026-10-27 |
| Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma | Phase 3 | Recruiting | NRG Oncology | 398 | 2026-07-16 | 2026-09-10 |
| A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS) Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Rhabdomyosarcoma | Phase 3 | Recruiting | Children's Oncology Group | 342 | 2026-07-14 | 2026-08-25 |
| Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Pencil Beam Scanning - Astrocytoma, IDH-Mutant, Grade 3 | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 408 | 2026-06-24 | 2026-10-02 |
| Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer Axitinib, Biospecimen Collection, Bone Scan - Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 718 | 2026-06-05 | 2026-06-11 |
| Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial Lutetium Lu 177 Vipivotide Tetraxetan, Biospecimen Collection, Patient Monitoring - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 1524 | 2026-03-31 | 2026-10-02 |
| Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer FOLFOXIRI, CAPOX, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin) - Locally Advanced Rectal Carcinoma | Phase 3 | Recruiting | J. W. A. Burger | 394 | 2026-03-16 | 2026-10-27 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer Bevacizumab, Biospecimen Collection, Carboplatin - Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 255 | 2026-01-27 | 2026-10-23 |
Showing 20 of 131. Sign in to see all of them.
Lung Neoplasms (11) · Prostatic Neoplasms (11) · Breast Neoplasms (8) · Carcinoma, Renal Cell (8) · Carcinoma, Non-Small-Cell Lung (6) · Squamous Cell Carcinoma of Head and Neck (5) · Urinary Bladder Neoplasms (5) · Brain Neoplasms (4) · Carcinoma (4) · Glioblastoma (4) · Neuroblastoma (4) · Oropharyngeal Neoplasms (4) · Carcinoma, Hepatocellular (3) · Colorectal Neoplasms (3) · Ganglioneuroblastoma (3)
National Cancer Institute (NCI) (47) · NRG Oncology (18) · Children's Oncology Group (16) · Alliance for Clinical Trials in Oncology (11) · ECOG-ACRIN Cancer Research Group (8) · SWOG Cancer Research Network (7) · Mayo Clinic (4) · Jonsson Comprehensive Cancer Center (2) · University Hospital, Strasbourg, France (2) · Andrei Iagaru (1) · Carina Mari Aparici (1) · City of Hope Medical Center (1) · Dana-Farber Cancer Institute (1) · Guy's and St Thomas' NHS Foundation Trust (1) · Hospices Civils de Lyon (1)
United States (117) · Canada (47) · Puerto Rico (23) · Australia (13) · New Zealand (7) · Hong Kong (6) · France (5) · Japan (5) · Saudi Arabia (5) · Guam (3) · Ireland (3) · South Korea (3) · Switzerland (3) · China (2) · India (2)
Elizabeth A Mullen (2) · Paul M Harari (2) · Vinai Gondi (2) · A. L Frazier (1) · Aarti Bhatia (1) · Adam Kinnaird, MD, PhD (1) · Al B Benson (1) · Alex F Herrera (1) · Amanda N Fader (1) · Andrea B Apolo (1) · Andrei Iagaru (1) · Anwaar Saeed (1) · Bhuvana A Setty (1) · Carina Mari Aparici, MD (1)
PMID 33395032, PMID 37505794, PMID 38421243, PMID 41747891, PMID 27811504, PMID 28686535, PMID 29025845, PMID 29211618, PMID 29376112, PMID 29552975, PMID 30332335, PMID 31197699, PMID 31449468, PMID 31478089, PMID 31676359, PMID 31748377, PMID 32597469, PMID 32875052, PMID 33006656, PMID 33151787, PMID 33152282, PMID 33161160, PMID 33370024, PMID 33843815, PMID 33878954, PMID 34028986, PMID 34149034, PMID 34292305, PMID 34340209, PMID 34357781, PMID 34406051, PMID 34604910, PMID 35170751, PMID 35290101, PMID 35304832, PMID 35383907, PMID 35613998, PMID 36155490, PMID 36302636, PMID 36416836, PMID 37035460, PMID 37185961, PMID 37222189, PMID 37555901, PMID 37598723, PMID 37783480, PMID 38107263, PMID 38131628, PMID 38423030, PMID 38475765
U10CA180868 (27), U10CA180886 (21), U10CA180820 (20), U10CA180888 (13), U10CA180821 (11), U10CA098543 (4), U10CA021115 (3), U10CA021661 (3), UG1CA189867 (3), U10CA180830 (2), U24CA196172 (2), 2025 (1), KL2TR001882 (1), P01DK068055 (1), P30CA033572 (1)